Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 678 Shares of Stock

Key Points

• John Fesko, an insider at Natera, sold 678 shares at an average price of $155.46, totaling approximately $105,401, reducing his ownership stake by 0.44% to 152,747 shares valued at around $23.75 million.
• Natera's recent earnings report revealed a loss of ($0.74) EPS, missing analysts' expectations, despite revenue increasing by 32.2% year-over-year to $546.6 million.
• The stock has been rated positively by analysts, with Evercore ISI upgrading it to a "strong-buy" and a consensus target price of $193.19, indicating strong future growth potential.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 678 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the transaction, the insider directly owned 152,747 shares in the company, valued at $23,746,048.62. The trade was a 0.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

John Fesko also recently made the following trade(s):

• On Monday, July 28th, John Fesko sold 1,710 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $239,075.10.
• On Monday, July 21st, John Fesko sold 339 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $47,219.31.
• On Tuesday, May 27th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $156.85, for a total transaction of $225,550.30.

Natera Trading Up 2.9%

NTRA stock traded up $4.58 during midday trading on Friday, hitting $163.02. The stock had a trading volume of 1,502,326 shares, compared to its average volume of 1,693,905. The firm has a market cap of $22.37 billion, a P/E ratio of -85.35 and a beta of 1.76. The business has a fifty day moving average price of $155.18 and a two-hundred day moving average price of $154.75. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) earnings per share. On average, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of analyst reports. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research note on Monday, July 28th. Royal Bank Of Canada upped their price target on shares of Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. One investment analyst has rated the stock with a sell rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and an average price target of $193.19.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. LRI Investments LLC purchased a new position in shares of Natera during the fourth quarter valued at approximately $29,000. Bank of Jackson Hole Trust purchased a new position in shares of Natera in the 1st quarter worth about $29,000. Rakuten Securities Inc. boosted its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC bought a new position in Natera during the first quarter valued at $32,000. Finally, TCTC Holdings LLC grew its stake in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.